The discovery of this biomarker--what could be a real coup for ovarian cancer patients worldwide--is described by HealthLinx as a coup for, well, HealthLinx.
people have suggested some numbers for the australian sales of HTX etc... that is misleading.
new developments change the course of bio stocks and the technology has not been ranked the best in asia only a week ago for nothing. also, its important to note why UK is important..
Australian diagnostics company HealthLinx Limited, along with researchers at the University of Liverpool, have just gotten word from the journal Clinical Science that their manuscript detailing the identification of a novel biomarker in ovarian cancer patients has been accepted for publication.
This means the company is now cleared to reveal the biomarker: anterior gradient protein 2 (AGR2). Based on early data, however, this biomarker could increase the performance of the company's OvPlex diagnostic test to greater than 97 percent accuracy.
HTX Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
